Comparative Pharmacology
Head-to-head clinical analysis: PSORCON E versus WESTCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PSORCON E versus WESTCORT.
PSORCON E vs WESTCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
Apply a thin film to affected area twice daily. Use for no longer than 2 consecutive weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing.
Terminal elimination half-life is 2-4 hours. Clinical context: Requires multiple daily applications for sustained effect; systemic accumulation unlikely with topical use.
Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%.
Primarily renal (70-90% as metabolites, <5% unchanged); minor biliary/fecal (10-20%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid